Viking Therapeutics’ obesity pill met weight reduction goals of its Phase 2 test, but gastrointestinal side effects led to high discontinuation rates. Even so, analysts see potential for a lower dose of the Viking drug as a maintenance therapy.
Higher doses of a Viking Therapeutics pill that targets two receptors led to greater weight loss without worsening safety or tolerability, according to Phase 1 results presented during the ObesityWeek conference. Meanwhile, an injectable version of this Viking drug is on track to Phase 3 testing.
Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.
The weight loss achieved by Viking Therapeutics’ obesity drug tops results posted by Eli Lilly’s Zepbound in its pivotal test. But Viking still needs to show its results can hold up in a larger Phase 3 clinical trial.